Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data.
Stephen B WilliamsKevin M WymerVidit SharmaJames P MoriartyBijan J BorahDaniel M GeynismanElizabeth R PlimackBrian A CostelloLance C PagliaroStephen A BoorjianPublished in: Cancer (2022)
We performed a benefit-to-cost analysis using evidence from a randomized controlled trial that compared two different chemotherapy treatments before bladder removal for bladder cancer that had invaded into the bladder muscle. Despite being more expensive and having a greater likelihood of toxicity, six cycles of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was more cost-effective (or had higher value) than four cycles of gemcitabine and cisplatin.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- muscle invasive bladder cancer
- rectal cancer
- spinal cord injury
- squamous cell carcinoma
- radiation therapy
- sentinel lymph node
- urinary tract
- lymph node
- electronic health record
- drug delivery
- oxidative stress
- high dose
- big data
- low dose
- data analysis
- deep learning
- artificial intelligence